MiRagen’s cobomarsen misses skin treatment target in Phase II trial for lymphoma
BOULDER — One of the most prominent drug candidates in the MiRagen Therapeutics Inc. (Nasdaq: MGEN) pipeline failed to show […]
Source: BizWest
Check out market updates
BOULDER — One of the most prominent drug candidates in the MiRagen Therapeutics Inc. (Nasdaq: MGEN) pipeline failed to show […]
Source: BizWest